Status:
COMPLETED
A Retrospective Study on Extranodal DLBCL
Lead Sponsor:
Ruijin Hospital
Conditions:
Lymphoma
Extranodal Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to prospectively collect clinical information of patients with extranodal DLBCL, assess the effectiveness of treatment for extranodal DLBCL in the real world, and explore the ...
Detailed Description
DLBCL is a highly common aggressive non-Hodgkin's lymphoma. For specific extranodal sites of DLBCL, traditional chemotherapy protocols often cannot provide satisfactory results for patients. The aim o...
Eligibility Criteria
Inclusion
- 1\. ≥ 18 years (including 18 years).
- 2\. Pathologically diagnosed with diffuse large B-cell lymphoma according to the 2016 WHO classification, including non-specific types and various special subtypes.
- 3\. Newly diagnosed DLBCL with involvement of extranodal organs.
- 4\. Patients who have received clinical treatment for lymphoma.
- Patients with measurable lesions, including at least one effective efficacy assessment.
Exclusion
- 1\. Patients receiving supportive care only.
- 2\. Patients who cannot obtain effective efficacy assessment data.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2023
Estimated Enrollment :
5023 Patients enrolled
Trial Details
Trial ID
NCT06549361
Start Date
May 1 2022
End Date
September 1 2023
Last Update
August 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China, 200000